首页>投融资
Ensoma
B轮
Ensoma Inc expanding the reach of the curative power of Genomic medicine by pioneering a next-generation in vivo approach using its Ingenious Vectors.In January 2023, the company had entered into a definitive agreement to acquire Twelve Bio ApS. In February 2023, Ensoma Inc acquired Twelve Bio.In February 2021, Ensoma had entered into collaboration with Takeda Pharmaceutical Company Limited.In January 2023, Ensoma had completed series A financing of $85 million.In February 2021, Ensoma had announced $70 million in Series A financing,
基本信息
-
公司全称Ensoma Inc
-
类型基因组药物研发商
-
产业领域药品研发/制造、生物药
-
公司人数15~50人
-
地址75 Kneeland Street,14Th Floor BOSTON MASSACHUSETTS 02111; US; Telephone: +16177663917;
-
联系电话
-
邮箱info@ensoma.com
-
成立时间2019-01-01
投融资
-
2023-05-16B轮5000万美元Bioluminescence VenturesKite PharmaDelos CapitalSymbiosis GroupGilead Sciences
-
2023-01-05未透露8500万美元Alexandria Venture InvestmentsCatalio Capital ManagementMirae Asset CapitalFred Hutchinson Cancer CenterBill and Melinda Gates FoundationQatar Investment Authority鱼鹰资管Solasta VenturesF-Prime CapitalSymbiosis GroupTakeda VenturesArix Bioscience5AM VenturesViking Global Investors
-
2021-02-11A轮7000万美元Alexandria Venture InvestmentsRIT Capital Partners鱼鹰资管F-Prime CapitalTakeda Ventures5AM VenturesViking Global Investors
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司，开发工程化单体 IgA 中性粒细胞接合器，以释放中性粒细胞对癌症的肿瘤杀伤能力，以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心（荷兰乌得勒支）进行的开创性工作，并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息